PharmaTelevision - MassBio: Robert Coughlin on Policy, Investment, Acquisitions and the Future of Biotechnology

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: MassBio: Robert Coughlin on Policy, Investment, Acquisitions and the Future of Biotechnology

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Robert Coughlin, President and CEO, about the the functions of MassBio. They discuss:

• Role of MassBio in policy environment

• Relationship with Bio

• How did the healthcare reform affect the members of MassBio?

• Working with FDA

• Economic crisis and changes in investments

• Is acquisition of local companies by large international pharma companies a good thing for MassBio?

• Future of Biotechnology industry and challenges for MassBio

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Functions of MassBio

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioPharm America in Boston. On this show I have Robert Coughlin, who is CEO of the Massachusetts Biotechnology Council otherwise known as MassBio, welcome to the show.

Robert Coughlin:

It's great to be here Fintan Walton, thank you.

Fintan Walton:

What is the function of MassBio?

Robert Coughlin:

Well our mission statement is clear, mission of MassBio is to create an environment in which all biopharma companies can achieve their upmost potential fairly general when you think about the companies and we represent well over 600 companies today. We represent the smallest of the small, the two person biotech company that just recently raised a small round of finance all the way to the biggest of the biopharma's and all of the large pharma companies and members of the trade association as well. So we need to provide services to help them succeed the big companies policy is very important, the smaller companies very important that we help them with their business needs, their innovation services, their economic development and their purchasing, so we try to do all of that for all of our member companies and we also have a communication strategy to educate the public as to what the definition of biotechnology really is? Why it's important to the economy? Why it's important to the patient population.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Robert K Coughlin

President

As President and CEO of the Massachusetts Biotechnology Council, Robert Coughlin 's mission is to foster a positive environment that enables each biotechnology company to achieve its full potential in Massachusetts, making the state a world center for biotechnology. He is very familiar with all areas of the Massachusetts life sciences super cluster and is a passionate advocate for research and the biotechnology community. Robert Coughlin has spent his career in both the public and private sectors, most recently serving as Undersecretary of Economic Development within Governor Deval Patrick's administration in 2007. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. In the legislature both healthcare and economic development were his priorities. In the world of business he specialized in the environmental services industry and moved on to capital management and venture capital. He has held senior executive positions in both fields. He is a graduate of the Massachusetts Maritime Academy where he majored in Marine Engineering, and is a Lieutenant in the United States Naval Reserve. Robert Coughlin has also been active in the community, having served on the boards of the Massachusetts Maritime Academy and Beth Israel Deaconess Hospital. He has served as the honorary chairman of the Great Strides Cystic Fibrosis Walk since 1996. In 2009 he co-chaired the Children's Hospital Boston signature event, Champions for Children's.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Massachusetts Biotechnology Council

The Massachusetts Biotechnology Council is an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research. Massachusetts Biotechnology Council are the leading advocate for the Bay State's world premier life science cluster and drive innovation by creating a forum for the biotechnology community to come together, educating the public and policy makers, influencing public policy and advancing the economic interests of individual companies, as well as the sector as a whole.